ADM Tronics Unlimited Joins Triotech Ventures Technology Consortium
NORTHVALE, N.J., Sept. 29, 2014 /PRNewswire/ -- ADM Tronics Unlimited, Inc. (OTCQB: ADMT) ADMT has announced that it has entered into an affiliation with Triotech Ventures, (triotechventures.com) ("Triotech") a technology consortium based in Cambridge, Massachusetts founded by Dr. Gianluca DeNovi, a recently appointed member of ADMT's Advisory Board.
The mission of Triotech is to support foreign medical technology companies with specialized services and finances to assist such companies to access the North American marketplace through a US-based subsidiary. For each accepted project, Triotech selects a team of partners, companies and professionals with specific expertise for a particular project. ADMT was selected to join the consortium to provide engineering, regulatory and manufacturing services for Triotech projects.
ADMT has already participated with Triotech in the founding of two new subsidiary companies:
Angiodroid America, Inc. was founded in February 2014 as a subsidiary to Angiodroid Srl of Bologna, Italy, (angiodroid.com) that has developed a patented medical device technology that allows automated injection of carbon dioxide ("CO2") into the blood stream for angiography procedures as an alternative to both the typically-used iodine contrast fluid, as well as manually injected CO2 . Iodine based contrast fluid can have unwanted effects and is not tolerated well by patients with allergic reactions. CO2 is not reported to have such negative effects but the manual procedure requires extreme caution. The Angiodroid device automates and simplifies the process of using CO2 providing physicians greater control and reduced dangers. The Angiodroid device is already available on the European market.
Biotechware America, Inc. was founded in June 2014 as a subsidiary of Biotechware, Srl of Turin, Italy, (biotechware.com) an early stage company that has developed a portable electrocardiography device ("ECG") trademarked "CardioPad" that can stream ECG test results through an internet service center. The device has potential application in many diverse fields including the military, pharmacies, assisted living facilities, and private homes. Differentiated from other electrocardiography devices, CardioPad is a smart medical device that can be a platform to offer a series of ancillary services to the ECG tests.
ADMT will be providing engineering and regulatory services to both Angiodroid and Biotechware through its participation in Triotech and will be the exclusive manufacturer of the devices for the North American market, once FDA clearance is achieved for these technologies.
ADMT specializes in electronic medical device design, development and manufacturing for diagnostic and therapeutic medical technologies at its FDA-Registered Medical Device Manufacturing Facility. The Company is a one-stop source for complete design, engineering, regulatory and manufacturing services. ADMT has a number of proprietary medical devices. These proprietary devices, conceived, designed and produced in-house, include therapeutic and diagnostic medical technologies in fields as diverse as audiology, physical medicine, wound therapy, neurology and urology.
About ADMT
ADMT is a diversified, technology-based developer and manufacturer of innovative technologies and products. Its core competency is its ability to conceptualize a technology, bring it through development, into manufacturing and commercialization, all in-house. ADMT has three Business Segments: Proprietary Electronic Medical Devices; Eco-Friendly, Safe, Water-Based Formulations; and, Design, Engineering, Regulatory and Manufacturing Services. The Company's headquarters, laboratories, medical device and manufacturing operations are located in Northvale, NJ. ADMT's multi-disciplinary team of engineers, researchers and technologists employ advanced technology infrastructure, such as 3-D solid prototyping, precision instrumentation and specialized software and peripherals for the research, development and commercialization of diversified technologies. Additional information is available at the Company's websites - admtronics.com and concepttoquantity.com.
Except for historical information contained herein, the matters set forth in this news release are "forward looking" statements (as defined in the Private Securities Litigation Reform Act of 1995). Although ADMT believes the expectations reflected in such forward looking statements are based upon reasonable assumptions, there can be no assurance that its expectations will be realized. Forward looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations. Factors that could contribute to such differences include those described from time to time in ADMT's filings with the SEC, news releases and other communications.
SOURCE ADM Tronics Unlimited, Inc.